drugset

drugset / Trial / NCT06285890

Phase I Study of HC-7366 for Acute Myeloid Leukemia

NCT06285890 ↗

Phase 1 Recruiting 18 enrolled M.D. Anderson Cancer Center HiberCell, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

To find a recommended dose of HC-7366 to patients with AML. The safety and effects of this drug combination will also be studied.

Timeline

Start: 2024-05-20
Primary completion: 2027-12-31
Completion: 2029-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HC-7366	Unknown	—	Oral

Indications